A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AAV / antibody-associated vasculitis

[Related PubMed/MEDLINE]
Total Number of Papers: 243
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AAV  (>> Co-occurring Abbreviation)
Long Form:   antibody-associated vasculitis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. EGPA, GPA, MPA, PICO
2021 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. EGPA, GPA, MPA, PICO
2021 An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis. GCs, LVV
2021 Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis. ANCA, TA
2021 ANCA Vasculitis Recurrence in Hemodialysis Patients: The Role of Rituximab. CKD
2021 ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia. ---
2021 ANCA-negative microscopic polyangiitis with diffuse alveolar hemorrhage masquerading as congestive heart failure. ANA, ANCA, MPA
2021 Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report. HIT, RPGN
2021 Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan. BMI, CI, HR, MPA
10  2021 Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. BVAS, CRP, FSTL1, MCS, PCS, SF-36
11  2021 Clinical features and outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in Chinese elderly and very elderly patients. ---
12  2021 Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. CI, RTX
13  2021 D-dimer predicts poor hospitalisation outcomes in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. ---
14  2021 Development of aortic valve stenosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement. AS, CKD, MPO-AAV
15  2021 Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis. AZA, ESRD, TAC
16  2021 Identifying the most influential gene expression profile in distinguishing ANCA-associated vasculitis from healthy controls. GADGs, HCs, iterativeWGCNA
17  2021 Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients. ILD
18  2021 Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review. HHV-8, KS
19  2021 New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report. ANCA
20  2021 Nutrition Risk Index Score at Diagnosis Can Effectively Predict Poor Prognosis in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ESRD, HR, NRI
21  2021 Olfactory dysfunction in antineutrophil cytoplasmic antibody-associated vasculitides: A review of the literature. OD
22  2021 Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. CI, HR, TMP/SMX
23  2021 Rare renal pathologic manifestation of antineutrophil cytoplasmic antibodies associated vasculitis as suppurative interstitial nephritis: A case report and review of the literature. ---
24  2021 Relationship between Renal Damage and Serum Complement C3 in Children with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. ESRD
25  2021 Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. OR
26  2021 Risk of Stroke in Systemic Necrotizing Vasculitis: A Nationwide Study Using the National Claims Database. HR, IRR, MPA, PAN, SIR, SNV
27  2021 Serological Biomarkers and Indices for the Current Activity and Prognosis of ANCA-Associated Vasculitis: Experience in a Single Centre in Korea. ---
28  2021 Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis. eGFR
29  2021 Subclinical CMV viremia is associated with increased nosocomial infections and prolonged hospitalization in patients with systemic autoimmune diseases. AD, CMV, SLE
30  2021 Systemic immune-inflammation index predicts a reduced risk of end-stage renal disease in Chinese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated vasculitis: A retrospective observational study. CRP, ESR, ESRD, MPO, SII
31  2021 Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in a 77-year-old man: A case report. SLE
32  2021 The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study. EGPA, GPA, MPA
33  2021 The impact of antineutrophil cytoplasmic antibody-associated vasculitis on employment and work disability in an Australian population. ---
34  2021 The novel fibrosis index at diagnosis may predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis without substantial liver diseases. CI, ESRD, HR, NFI
35  2021 The prevalence of metabolic syndrome is increased in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. IDF, MetS, NCEP ATP III
36  2021 Vitamin D Levels in Patients With Small and Medium Vessel Vasculitis. CryV, HS, IgAV, PAN, RA
37  2020 A Dutch consensus statement on the diagnosis and treatment of ANCA-associated vasculitis. ---
38  2020 Association between Functional Independence Measure and mortality in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-center observational study. FIM
39  2020 Association between statin use and incidence of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center retrospective cohort study. ---
40  2020 Atherogenic index of plasma predicts cerebrovascular accident occurrence in antineutrophil cytoplasmic antibody-associated vasculitis. AIP, CAD, CVA
41  2020 Circulating nicotinamide adenine dinucleotide-ubiquinone oxidoreductase chain 6 is associated with disease activity of anti-neutrophil cytoplasmic antibody-associated vasculitis. ND6, PH
42  2020 Clinical characteristics of patients with myalgia as the initial manifestation of small and medium-sized vasculitis: a retrospective study. MPA, PAN
43  2020 Clinical significance and influencing factors of fibrinogen in ANCA-associated vasculitis: A single-center retrospective study from Southwest China. eGFR, ESKD, FIB, MANOVA, ROC
44  2020 Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. FSGS, GN, IgAN, LN, MCP-1, MN, MPGN, TGF-beta1
45  2020 Comparison of lung microbiota between antineutrophil cytoplasmic antibody-associated vasculitis and sarcoidosis. BALF, BVAS, HMP
46  2020 Distinct HLA and non-HLA associations in different subtypes of ANCA-associated vasculitides in North India. CTLA-4, GPA, HLA, PCR-SSP, PR3, PTPN22
47  2020 Double Filtration Plasmapheresis in the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Dysfunction. DFPP, ESKD, HR, TPE
48  2020 Efficacy of the fibrosis index for predicting end-stage renal disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ESRD, FI
49  2020 Enhanced fallopian canal as a potential marker for temporal bone vasculitis. CE-3D-GRE
50  2020 Evaluation of body composition using computed tomography in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. BMI, CI, CT, OR, SAT, SMA, VAT
51  2020 Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement: A Single-Center Cross-Sectional Study. CRS, ENT, NOSE, QoL, SNOT-22
52  2020 Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. OR
53  2020 Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. GPA, MPA
54  2020 Multimorbidity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Longitudinal, Multicenter Data Linkage Study. ---
55  2020 Prevalence of Osteopenia in Drug-Naive Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Monocentric Study. BMI, OR
56  2020 Rituximab use in adult glomerulopathies and its rationale. FSGS, IMN, KDIGO, LN, MCD, MPGN, RCTs, RTX
57  2020 Serum granzyme B is associated with otorhinolaryngological, pulmonary, and renal involvement of antineutrophil cytoplasmic antibody-associated vasculitis. BVAS, FFS, GrB
58  2020 Serum interleukin-16 significantly correlates with the Vasculitis Damage Index in antineutrophil cytoplasmic antibody-associated vasculitis. BVAS, FFS, IL, SF-36, VDI
59  2020 Serum vitamin D level correlates with disease activity and health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis. BVAS, CRP, MCS
60  2020 Severe proximal muscle weakness with normal CK as a presenting feature of ANCA-associated vasculitis. ---
61  2020 Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Is Inversely Correlated with the Activity of ANCA-Associated Vasculitis. BVAS, LDL, sLOX1
62  2020 Thai Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Outcomes and Risk Factors for Mortality. BVAS
63  2020 The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study. BVAS, ESR, NLR, ROC, SCr
64  2020 Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis. ESRD, HR
65  2020 Tubulointerstitial damage and interstitial immune cell phenotypes are useful predictors for renal survival and relapse in antineutrophil cytoplasmic antibody-associated vasculitis. ESRD, RR
66  2020 Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis. BIPQ, GCA, IPQ-R, MFI, PGA, PtGA, RP, TA
67  2020 Vascular endothelial growth factor (VEGF)-A and VEGF-A165b are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study. EGPA, sVEGF-A, VEGF
68  2019 A Case of Heparin-Induced Thrombocytopenia That Developed in the Therapeutic Course of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. HIT
69  2019 Association of serum high mobility group box 1 levels with disease activity and renal involvement in patients with systemic vasculitis. EH, HC, HMGB1, hs-CRP, PAN, SCr, TA, VAs
70  2019 Azathioprine hypersensitivity syndrome in anti-myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis. ---
71  2019 CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients. F-R, GPA, NR
72  2019 Citrullinated histone H3 expression in anti-neutrophil cytoplasmic antibody-associated vasculitis in older Japanese autopsy patients. citH3
73  2019 Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases. GN, NETs, SLE
74  2019 Comparison of Radiological and Histological Findings of Lung Parenchyma in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. CT, EGPA, GPA, MPA
75  2019 Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry). BVAS, FFS, ROC
76  2019 Early and late effects of therapeutic plasma exchange in patients with systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis: A single-center experience. AKI, SLE, TPE
77  2019 Efficacy of Plasma Exchange in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. ---
78  2019 Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. EETs, EETs, EGPA, GPA, MPA
79  2019 Inflammation level and renal function injury in antineutrophil cytoplasmic antibody-associated vasculitis:a correlation with low albumin and high-density lipoprotein. Cr
80  2019 Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis. CI, HR, OC
81  2019 Prognostic nutritional index is associated with disease severity and relapse in ANCA-associated vasculitis. BVAS, CRP, ESR, OR, PNI
82  2019 Prognostic Value of Microscopic Hematuria after Induction of Remission in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. ESRD, HR, PIGN, RR
83  2019 Relationship Between Immunosuppressive Therapy and the Development of Infectious Complications Among Patients with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Single-center, Retrospective Observational Study. CI, OR
84  2019 Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. CI, CMV, GPA, OR
85  2019 Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010-2018. SIRs
86  2019 Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database. CS, OIs, OR, PSL
87  2019 Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series. ANCAs, CYC, ESRD
88  2019 Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series. CNS, CYC, RTX
89  2019 Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies. ---
90  2019 Systemic Lupus Erythematosus (SLE) and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) Overlap Syndrome: Case Report and Review of the Literature. GPA, MPA, SLE
91  2019 The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey. CHCC, MPO, PR3
92  2019 The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. GBTM
93  2019 The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis. ---
94  2019 Treatment Strategies in ANCA-Associated Vasculitis. ---
95  2019 Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. ICF, OMERACT
96  2018 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. CPG, GC, IVCY
97  2018 Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review. GPA
98  2018 Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ANCA, GM-CSF, GPA, IL-18BP, IL-6, MPA, MPO-ANCA, NGAL, NGFbeta, PR3-ANCA, sICAM-1, sIL-2Ralpha, sTNF-RII, TARC
99  2018 Clinical features and outcomes in patients with elderly-onset anti-neutrophil cytoplasmic antibody-associated vasculitis. ---
100  2018 Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ---